PharmaEssentia Medical Affairs | Clinical Trials in Essential Thrombocythemia

Our Pipeline

Clinical Trials in Essential Thrombocythemia (ET)

Our commitment to scientific excellence is the basis for our ongoing clinical research. We are deeply appreciative of the study sites, investigators, patients, caregivers, and clinicians who support our efforts through their participation. Learn more about our trial data and currently enrolling trials below.

Currently Enrolling Trials

A Phase 3, open-label, multicenter, randomized, active-controlled trial assessing the efficacy, safety, tolerability, and pharmacokinetics of ropeginterferon alfa-2b-njft after 12 months of treatment compared with anagrelide (ANA) as second-line therapy for adult patients with ET who have shown resistance or intolerance to hydroxyurea (HU). NCT04285086

For more information about SURPASS ET:

A Phase 2b, single-arm, multicenter trial assessing the efficacy, safety, and tolerability of ropeginterferon alfa-2b-njft in adult patients with ET in the US and Canada. NCT05482971

For more information about EXCEED ET:

You are now leaving this site and being directed to a site not maintained by PharmaEssentia.

PharmaEssentia is not responsible for content or privacy policies on other sites.